Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

445results about "Biological preparation purge" patented technology

Microfluidic device for cell separation and uses thereof

The invention features methods for separating cells from a sample (e.g., separating fetal red blood cells from maternal method begins with the introduction of a sample including cells into one or more microfluidic channels. In one embodiment, the device includes at least two processing steps. For example, a mixture of cells is introduced into a microfluidic channel that selectively allows the passage of a desired type of cell, and the population of cells enriched in the desired type is then introduced into a second microfluidic channel that allows the passage of the desired cell to produce a population of cells further enriched in the desired type. The selection of cells is based on a property of the cells in the mixture, for example, size, shape, deformability, surface characteristics (e.g., cell surface receptors or antigens and membrane permeability), or intracellular properties (e.g., expression of a particular enzyme).
Owner:THE GENERAL HOSPITAL CORP

Compositions and methods for treating and diagnosing cancer

InactiveUS20080064049A1Increased ALDH activityEnzymologyArtificial cell constructsSolid tumorCancer research
The present invention relates to compositions and methods for characterizing, treating and diagnosing cancer. In particular, the present invention provides a cancer stem cell profile, as well as novel stem cell cancer markers useful for the diagnosis, characterization, prognosis and treatment of cancer and in particular the targeting of solid tumor stem cells.
Owner:RGT UNIV OF MICHIGAN +1

Preparation of a cell concentrate from a physiological solution

The present invention is directed to methods and compositions regarding the preparation of an cell concentrate, such as, for example, an osteogenic cell concentrate, from a physiological solution, such as bone marrow aspirate, blood, or a mixture thereof. In specific embodiments, the invention provides methods and compositions utilizing two physiological solution-processing techniques, particularly in a point of care environment, wherein centrifugation is not employed.
Owner:SMITH & NEPHEW INC +1

Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders

Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES +3

Allogeneic stem cell transplants in non-conditioned recipients

Methods, cells, and compositions of matter are disclosed for performing stem cell transplants in patients that have not been previously immunosuppressed. Specific disclosed are methods of matching, methods of treating the stem cell graft, and use of engraftment-assisting cells and agents.
Owner:XON CELLS

Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase

The present invention relates to the use of tissue non-specific alkaline phosphatase (TNAP) as a marker for identifying and / or isolating adult multipotential cells. The present invention also relates to cell populations enriched by methods of the present invention and therapeutic uses of these cells.
Owner:MESOBLAST

Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potentatial of a cancer thereof

The present invention relates to novel methods and compositions for detection and isolation of cancer cells with metastatic potential. The invention further relates to assays for measuring the metastatic potential of such cancer cells and drug screening assays for the identification of agents having anti-metastatic potential. The present invention further provides methods and compositions for inhibiting the metastatic potential of cancer cells by modulating the activity of serine integral membrane proteases [(SIMP) consisting of seprase and dipedidyl peptidase IV (DPPIV)]expressed on the surface of metastasizing cancer cells.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK

Methods for Manipulating Phagocytosis Mediated by CD47

Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd

InactiveUS20050118142A1Host engraftmentRisk minimizationBiocideVertebrate cellsT cellLeukemia
The present invention provides for cellular compositions which facilitate engraftment of hematopoietic stem cells from a syngeneic, allogeneic or xenogeneic donor. The cellular compositions of the invention facilitate engraftment while minimizing the risk of graft versus host disease in the graft recipient. According to a preferred embodiment of the invention, a cell composition is provided, which cell composition comprises hematopoietic stem cells, such as CD34+ cells and / or facilitating cells, in combination with αβ TCR+ T cells. The invention also relates to methods of using the cellular compositions of the invention to induce donor specific tolerance in a recipient, thus allowing the transplantation of donor organs, cells and tissues. Also disclosed are methods of treating leukemia and cancer as well as infectious diseases caused by viruses.
Owner:JEWISH HOSPITAL HEALTHCARE SERVICES

Coating material for leukocyte removal filter and the filter

It is intended to provide a polymer for coating a leukocyte removal filter material which is excellent in the capability of removing leukocytes. It is further intended to provide a filter whereby both of leukocytes and platelets can be highly efficiently removed from a blood product containing leukocytes and platelets. The above objects can be achieved by using a polymer for coating a leukocyte removal filter material which comprises a unit originating in a hydrophobic polymerizable monomer, a unit originating in a polymerizable monomer containing a basic nitrogen-containing part, and a unit originating in a polymerizable monomer containing a protonic neutral hydrophilic part.
Owner:ASAHI KASEI MEDICAL CO LTD

Continuous flow chamber device for separation, concentration, and/or purfication of cells

The present invention relates to methods and apparatuses for cell separation. In particular, the invention relates to separation of a particular cell type from a mixture of different cell types based on the differential rolling property of the particular cell type on a substrate coated with molecules that exhibits adhesive property with the particular cell type. This technology is adaptable for use in implantable shunts and devices for cell trafficking or tumor neutralization.
Owner:UNIVERSITY OF ROCHESTER

Particle/cell separation device and compositions

A particle / cell separation device is described which is particularly adapted for neutrophil depletion from a preparation of whole blood or platelet-rich plasma. Also described are blood and platelet rich plasma compositions produced using the device which are neutrophil-depleted.
Owner:BLUE ENGINE BIOLOGICS LLC

Prevention, decrease, and/or treatment of immunoreactivity by depleting and/or inactivating antigen presenting cells in the host

The invention includes compositions and methods for depleting and / or inactivating antigen presenting cells, or for otherwise impairing the biological function of antigen presenting cells, which compositions are useful for treatment of graft versus host disease and other immune diseases.
Owner:YALE UNIV

Regulatory b cells and their uses

The present invention relates to a phenotypically distinct CD1dhigh CD5+ B cell subset that regulates T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-IO). The invention also relates to the use of these IL-IO producing regulatory B cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of these regulatory B cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of this subset of regulatory B cells, or inhibition of their IL-IO production can be used to upregulate immunodeficient conditions, and / or to treat tumors / cancer. Diagnostic applications also are encompassed.
Owner:DUKE UNIV

Continuous flow chamber device for separation, concentration, and/or purification of cells

The present invention relates to methods and apparatuses for neutralizing cancer cells. In particular, the invention relates to separating of cancer cell type from a mixture of different cell types based on the differential rolling property of cancer cell on a substrate coated with a first molecules that exhibits adhesive property with the particular cell type and neutralizing the cancer cell by a second molecule that is also coated on the substrate. This technology is adaptable for use in vivo, in vitro, or ex vivo tumor neutralization.
Owner:UNIVERSITY OF ROCHESTER

mAb-DRIVEN CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING ENGINEERED IMMUNE CELLS

A polypeptide encoding a chimeric antigen receptor (CAR) comprising at least one extracellular binding domain that comprises a scFv formed by at least a VH chain and a VL chain specific to an antigen, wherein said extracellular binding domain comprises at least one mAb-specific epitope.
Owner:CELLECTIS SA +1

Hematopoietic cell composition for use in transplantation

Cell compositions consisting essentially of mammalian hematopoietic CXCR4+ stem and progenitor capable to migrate in response to stromal-derived factor 1 (SDF-1) and / or capable to adhere to stromal cells in response to an adhesion-inducing agent, are provided for clinical transplantation. Hematopoietic CXCR4− / low stem and progenitor cells can be converted into CXCR4+ cells by stimulation with a suitable agent. The composition consists preferably of human CD38− / low CXCR44 cells.
Owner:YEDA RES & DEV CO LTD

Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions

Reovirus can be used to selectively remove ras-mediated neoplastic cells from a cellular composition. It is of particular interest to purge autographs which may contain neoplastic cells with reovirus before transplanting the autographs back into the recipient, thereby reducing the risk of introducing or reintroducing neoplastic cells into the recipient.
Owner:ONCOLYTICS BIOTECH

Alteration of cell membrane with B7

Methods and compositions are provided for the persistent modification of cell membranes with exogenous proteins so as to alter the function of the cell to achieve effects similar to those of gene therapy, without the introduction of exogenous DNA. DNA sequences, the proteins and polypeptides embodying these sequences are disclosed for modulating the immune system. The modulations include down-regulation, up-regulation and apoptosis.
Owner:UNIV OF LOUISVILLE RES FOUND INC

Cell Culture Media Supplement and Method of Molecular Stress Control

A novel class of agents has been identified to serve as cell-guard agents and / or target-specific supplements to increase cell quality and yield, as well as select for target cell populations. Laboratory experiments have demonstrated the use of cell-guard agents and / or target-specific supplements in the bioprocessing of cells as well as in selecting out a desired cell population. Several potential additive agents (both natural and synthetic) have been identified during these studies, including Vitamin D3, NAC, resveratrol, salubrinal, AKT, and tunicamycin (among others) that hold promise for application in cell models. In one embodiment, hypothermic stress regimes are utilized. In another embodiment, normothermic conditions are utilized while other stressors are tested in the processing. The methods of maintaining mass cell cultures and / or selecting out particular cell populations for further research and clinical use represents an important step in therapeutic discovery. The cell-guard agents are process-matched and cell-matched to protect and / or select particular cells during laboratory and clinical manipulation. The components modulate cell stress and survival pathways.
Owner:CPSI HLDG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products